- BioPharm International-08-01-2002
- Volume 15
- Issue 8
Making Regulatory Compliance a Core Process: Director and Officer Liability Exposure
by Joseph F. Noferi, Edward R. Arling, and Ralph H. Dillon, Pharmacia GS API Biopharma, global supply, and Daniel E. Worden, Worden Enterprises FDA is no longer complacent, punishing noncompliant companies with puny fines, those small slaps at the financial bottom line. FDA?s thunder now includes multimillion dollar fines, permanent injunctions, and prison sentences for senior executives. Companies that emerge as winners in today?s environment are those that treat compliance and risk management with the same flawless planning and execution that they use for their business plans and their financial investments.
Articles in this issue
about 23 years ago
Guest Editorial: Quality Agreements with Contract Laboratoriesabout 23 years ago
Inside Washington: User Fee Program Seeks to Spur Biotech Developmentabout 23 years ago
Analytical Advances: Mapping Proteins – the 2-D Electrophoresis Issueabout 23 years ago
Your Vested Interests: Gorillas In Our MidstNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.